The Syndax team is comprised of senior executives with extensive experience in oncology and leading the field of epigenetics.

Briggs Morrison, M.D.
Chief Executive Officer

Briggs Morrison, M.D. joined Syndax as Chief Executive Officer in 2015. Prior to joining Syndax, he served as Executive Vice President, Global Medicines Development & Chief Medical Officer at AstraZeneca from 2012 to 2015, leading the company’s global, late-stage development organization and serving as a member of the AstraZeneca Senior Executive Team. He previously held a number of positions at Pfizer Inc. from 2007 to 2012 that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business, and also served in roles of increasing responsibility at Merck Research Laboratories from 1995 to 2007, ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. Dr. Morrison is Chairman of the Board of Transcelerate, an industry-funded company charged with improving aspects of clinical trials, a member of the Executive Committee of CTTI (the Clinical Trials Transformation Initiative sponsored by FDA) and is on the Board of ACRES (Alliance for Clinical Research Excellence and Safety). Dr. Morrison received a B.S. in biology from Georgetown University, Phi Beta Kappa, and an M.D. from the University of Connecticut, followed by an internship and residency in Internal Medicine at the Massachusetts General Hospital, a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and a post-doctoral research fellowship in Genetics at Harvard Medical School.